BFBen Fehnert

Ben Fehnert

*This is an algorithmically generated author record based on publicly available information.

Ben Fehnert has a total of 47 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Real-World Implementation and Evaluation of a Digitally Enabled Care Pathway to Improve Depression Management in Primary Care: Controlled Pre-Post Analysis of the Pathway Platform

    by Rasha Khatib, Christopher Blair, Maggie McCue, Ben Fehnert, James King, Lara Zaki, Lambros Chrones, Anit Roy, Michael L Martin, Ramona Donovan, et al.

    Background: Measurement-based care (MBC) and shared decision-making can improve clinical outcomes for patients with major depressive disorder (MDD) in primary care. However, primary care providers often have limited time to administer patient-reported outcome measures recommended for MBC. Digital health tools like the Pathway Platform can help facilitate MBC and patient-provider engagement, aiding enhanced shared decision-making. Objective: This study aimed to assess whether implementation of the Pathway Platform improves adherence to MBC practices in primary care clinics compared with standard care. Secondary objectives included whether implementation of Pathway Platform improves additional clinical process measures and MDD remission and response. Methods: This real-world, longitudinal implementation study screened participants aged ≥18 years with MDD who started an antidepressant or switched within 3 months in primary care clinics in Illinois. Data were collected 6 months retrospectively (from the preimplementation period) using electronic health records and manual chart reviews (control cohort), and 6 months prospectively (postimplementation, conducted 2021 to 2023) using electronic health records, manual chart reviews, and the Pathway Platform mobile app (Pathway cohort). The primary outcome was the proportion of participants with ≥2 completed 9-Item Patient Health Questionnaires (PHQ-9) at 6 months. Secondary outcomes included health care resource usage, patient-provider engagement (13-Item Patient Activation Measure [PAM-13]), and overall functioning (Work and Social Adjustment Scale [WSAS]). Exploratory outcomes included cognitive functioning (5-Item Perceived Deficits Questionnaire–Depression [PDQ-D-5]) and MDD symptom improvement. Results: The control cohort had 90 participants (58% female), and the Pathway cohort had 89 (80% female). A significantly higher proportion of Pathway cohort participants completed ≥2 PHQ-9s than control cohort participants (19%, n=17 vs 12%, n=11; P=.01). All Pathway cohort participants completed ≥1 PHQ-9 assessment, and 45% (n=40) of participants opened the app at least once per week. Pathway participants were significantly less likely than controls to have behavioral health referrals (9%, n=8 vs 23%, n=21; P=.01). Patient-provider engagement assessed using PAM-13 showed significant improvement from baseline to 6 months among Pathway participants (n=54; median change from baseline 4, Q1 0 to Q3 9.2], 95% CI 0-4.9; P<.001). Median change from baseline to last available scores for WSAS (–4.0, Q1 –9 to Q3 1; P<.001) and PDQ-D-5 (–2, Q1 –6 to Q3 0; P<.001) showed improvement among patients in the Pathway cohort. Median PHQ-9 total score at 6 months was significantly lower in the Pathway cohort than the control cohort (6.5, Q1 3.0 to Q3 12.5 vs median 17.0, Q1 14.5 to Q3 20.0; P=.02), indicating improvement in MDD symptoms. Conclusions: The Pathway Platform significantly improved PHQ-9 completion rates, patient-provider engagement (improved PAM-13 scores), and clinical outcomes for MDD, with fewer behavioral health referrals. These findings suggest that use of the Pathway Platform supports improved MBC, offering a promising tool to improve MDD outcomes in primary care settings. Trial Registration: ClinicalTrials.gov NCT04891224; https://clinicaltrials.gov/ct2/show/NCT04891224 International Registered Report Identifier (IRRID): DERR1-10.2196/43788

  • Open Access

    Comparing Usual Care With Coordinated Clinician and Patient Use of Mobile Technology in Primary Care for Patients With Major Depressive Disorder: Practice-Based Pilot Study

    by Angela M Lanigan, Elisabeth F Callen, Melissa K Filippi, Elise A Robertson, Tarin L Clay, Andrea Nederveld, Ben Fehnert, Lambros Chrones, Michael L Martin, Maggie McCue, et al.

    Background: Major depressive disorder (MDD) affects millions of Americans each year and is often diagnosed and treated in primary care. Evidence shows that self-management techniques, shared decision-making (SDM), and goal setting are effective strategies for managing MDD, but the required collaboration between patients and primary care clinicians can be difficult. Primary Care Path is a program for supporting depression management in primary care that includes a patient-facing mobile app and an accompanying care team–facing web interface. Leveraging programs that provide clinician-facing software with companion patient-facing mobile technology may help patients and physicians align depression treatment and management goals, support effective SDM, alleviate barriers, and improve both clinical care and patient outcomes. Objective: To pilot-test the use of Primary Care Path for MDD management in primary care and evaluate the impact of its use on depression treatment, symptoms, goal setting and attainment, and SDM. Methods: Four primary care clinical practices in the United States were assigned to program use (2 practices; intervention) versus usual care (2 practices; control). Intervention practices used the Primary Care Path program in their clinics and engaged patient participants in app use for 18 weeks. Clinical care teams engaged with the patient-informed program portal primarily during patient encounters (in-person, virtual or calls). Patient participants were smartphone users aged 18 years and older who were being treated for MDD. Patient participants received online surveys (medication changes, Patient Health Questionnaire-9 [PHQ-9], goal setting and attainment questions, and Shared Decision-Making Questionnaire-9 [SDM-Q-9]) at baseline, 6, 12, and 18 weeks. Results: A total of 76 patient participants (34 intervention; 42 control) were enrolled; the majority were female (27/34, 79%; 32/42, 76%), White (31/34, 91%; 40/42, 95%), non-Hispanic/Latino/a (29/34, 85%; 40/40, 100%), and employed (26/34, 77%; 34/42, 81%). Control patient participants’ conversations with their medical providers increased over the study period, while intervention patient conversations with their medical providers decreased over time. At week 18, intervention participants felt more successful than control in achieving their personalized treatment goals. More intervention patient participants initiated antidepressant medication by weeks 12 ( P =.03) and 18 ( P =.04) and switched medications by weeks 6 ( P =.009) and 12 ( P =.04) versus control. All patient participants demonstrated significant improvement in PHQ-9 scores throughout the study period ( P <.001), with no difference in change by group. Clinicians and patients indicated using the program to support SDM, but no significant differences were observed in SDM-Q-9 between intervention and control. Conclusions: Preliminarily, the use of this digital health program related to earlier medication optimization, earlier conversations between patients and medical providers, and patient attainment of goals that matter most to them, indicating that coordinated use of the program by both patients and clinical team members may enhance MDD management in primary care clinical settings.

  • Open Access

    Real-World Implementation and Evaluation of a Digitally Enabled Care Pathway to Improve Depression Management in Primary Care: Controlled Pre-Post Analysis of the Pathway Platform (Preprint)

    by Rasha Khatib, Christopher Blair, Maggie McCue, Ben Fehnert, James King, Lara Zaki, Lambros Chrones, Anit Roy, Michael L Martin, Ramona Donovan, et al.

    BACKGROUND Measurement-based care (MBC) and shared decision-making can improve clinical outcomes for patients with major depressive disorder (MDD) in primary care. However, primary care providers often have limited time to administer patient-reported outcome measures recommended for MBC. Digital health tools like the Pathway Platform can help facilitate MBC and patient-provider engagement, aiding enhanced shared decision-making. OBJECTIVE This study aimed to assess whether implementation of the Pathway Platform improves adherence to MBC practices in primary care clinics compared with standard care. Secondary objectives included whether implementation of Pathway Platform improves additional clinical process measures and MDD remission and response. METHODS This real-world, longitudinal implementation study screened participants aged ≥18 years with MDD who started an antidepressant or switched within 3 months in primary care clinics in Illinois. Data were collected 6 months retrospectively (from the preimplementation period) using electronic health records and manual chart reviews (control cohort), and 6 months prospectively (postimplementation, conducted 2021 to 2023) using electronic health records, manual chart reviews, and the Pathway Platform mobile app (Pathway cohort). The primary outcome was the proportion of participants with ≥2 completed 9-Item Patient Health Questionnaires (PHQ-9) at 6 months. Secondary outcomes included health care resource usage, patient-provider engagement (13-Item Patient Activation Measure [PAM-13]), and overall functioning (Work and Social Adjustment Scale [WSAS]). Exploratory outcomes included cognitive functioning (5-Item Perceived Deficits Questionnaire–Depression [PDQ-D-5]) and MDD symptom improvement. RESULTS The control cohort had 90 participants (58% female), and the Pathway cohort had 89 (80% female). A significantly higher proportion of Pathway cohort participants completed ≥2 PHQ-9s than control cohort participants (19%, n=17 vs 12%, n=11; P=.01). All Pathway cohort participants completed ≥1 PHQ-9 assessment, and 45% (n=40) of participants opened the app at least once per week. Pathway participants were significantly less likely than controls to have behavioral health referrals (9%, n=8 vs 23%, n=21; P=.01). Patient-provider engagement assessed using PAM-13 showed significant improvement from baseline to 6 months among Pathway participants (n=54; median change from baseline 4, Q1 0 to Q3 9.2], 95% CI 0-4.9; P<.001). Median change from baseline to last available scores for WSAS (–4.0, Q1 –9 to Q3 1; P<.001) and PDQ-D-5 (–2, Q1 –6 to Q3 0; P<.001) showed improvement among patients in the Pathway cohort. Median PHQ-9 total score at 6 months was significantly lower in the Pathway cohort than the control cohort (6.5, Q1 3.0 to Q3 12.5 vs median 17.0, Q1 14.5 to Q3 20.0; P=.02), indicating improvement in MDD symptoms. CONCLUSIONS The Pathway Platform significantly improved PHQ-9 completion rates, patient-provider engagement (improved PAM-13 scores), and clinical outcomes for MDD, with fewer behavioral health referrals. These findings suggest that use of the Pathway Platform supports improved MBC, offering a promising tool to improve MDD outcomes in primary care settings. CLINICALTRIAL ClinicalTrials.gov NCT04891224; https://clinicaltrials.gov/ct2/show/NCT04891224 INTERNATIONAL REGISTERED REPORT DERR1-10.2196/43788

  • Open Access

    Patient and Care Team Perspectives of Barriers to and Facilitators for the Implementation of a Digital Health Program for Depression in Primary Care: Qualitative Study

    by Andrea Nederveld, Elise A Robertson, Angela M Lanigan, Elisabeth F Callen, Tarin L Clay, Ben Fehnert, Lambros Chrones, Michael L Martin, Margaret McCue, Christina M Hester, et al.

    Background: Depression is pervasive, and rates are rising in the United States. Most people with depression receive care from primary care clinicians, but gaps in the quality of care exist. Team-based approaches to depression care have been shown to aid in treatment and management; yet, challenges exist in implementation. Digital health apps have been shown to be effective in improving depression symptoms and enhancing patient engagement in some populations. Many, however, do not share data with clinical care teams. Objective: This study aimed to understand the barriers to and facilitators for implementation of a digital health program that supports coordinated use by clinical care teams and patients, via a mobile app and care team–facing web interface, for depression in primary care. Methods: This study was part of a larger intervention study that included 4 primary care practices: 2 intervention and 2 control sites. The intervention sites used a patient-facing mobile app and a care team–facing web interface, and the control sites continued usual care. The study team conducted interviews from May to October 2021. Patient and care team participants were recruited toward the end of their study involvement. Separate semistructured interview guides were developed for patient and care team participants. Interviews were recorded and transcribed. Data were coded using Atlas.ti.9, and data analysis was completed using a grounded theory approach. Results: Interviews with patient (n=8) and care team (n=8) participants revealed 3 main topics for program implementation: app/interface usability, tracking, and program recommendations. For app/interface usability, overall, navigation for both patient and care team participants was simple and straightforward. Although app content was relevant, patient participants desired additional educational resources and information to aid in their depression treatment and management. In terms of tracking, care team participants indicated that data obtained via the interface enabled them to monitor patients in between visits; and in some circumstances, these data facilitated conversations with patients about treatment plans. Tracking medication adherence differed among patient participants due to established routines of taking medications consistently, lack of motivation to track, or lack of interest in tracking. Care team participants reported the ability to respond more quickly to side effects. Patients commented on tracking difficulties: confusing response options, insufficient goal attainment response options, not being able to provide details or write notes, and no ability to change goals. Some patient and care team participants perceived that tracking encouraged communication with one another; others perceived tracking as having no impact on shared decision-making. Conclusions: Results suggest implementation of a digital health program for depression treatment and management in primary care practices could impact patient medication adherence, produce faster turnaround time for medication optimization, encourage goal setting, and foster communication between patients and care team members. Program enhancements could optimize patient and care team member engagement.


  • Open Access

    Characterizing Longitudinal Patterns in Cognition, Mood, And Activity in Depression With 6-Week High-Frequency Wearable Assessment: Observational Study

    by Francesca Cormack, Maggie McCue, Caroline Skirrow, Nathan Cashdollar, Nick Taptiklis, Tempest van Schaik, Ben Fehnert, James King, Lambros Chrones, Sara Sarkey, et al.

    Background: Cognitive symptoms are an underrecognized aspect of depression that are often untreated. High-frequency cognitive assessment holds promise for improving disease and treatment monitoring. Although we have previously found it feasible to remotely assess cognition and mood in this capacity, further work is needed to ascertain the optimal methodology to implement and synthesize these techniques. Objective: The objective of this study was to examine (1) longitudinal changes in mood, cognition, activity levels, and heart rate over 6 weeks; (2) diurnal and weekday-related changes; and (3) co-occurrence of fluctuations between mood, cognitive function, and activity. Methods: A total of 30 adults with current mild-moderate depression stabilized on antidepressant monotherapy responded to testing delivered through an Apple Watch (Apple Inc) for 6 weeks. Outcome measures included cognitive function, assessed with 3 brief n-back tasks daily; self-reported depressed mood, assessed once daily; daily total step count; and average heart rate. Change over a 6-week duration, diurnal and day-of-week variations, and covariation between outcome measures were examined using nonlinear and multilevel models. Results: Participants showed initial improvement in the Cognition Kit N-Back performance, followed by a learning plateau. Performance reached 90% of individual learning levels on average 10 days after study onset. N-back performance was typically better earlier and later in the day, and step counts were lower at the beginning and end of each week. Higher step counts overall were associated with faster n-back learning, and an increased daily step count was associated with better mood on the same (P<.001) and following day (P=.02). Daily n-back performance covaried with self-reported mood after participants reached their learning plateau (P=.01). Conclusions: The current results support the feasibility and sensitivity of high-frequency cognitive assessments for disease and treatment monitoring in patients with depression. Methods to model the individual plateau in task learning can be used as a sensitive approach to better characterize changes in behavior and improve the clinical relevance of cognitive data. Wearable technology allows assessment of activity levels, which may influence both cognition and mood.


  • Open Access

    User-Centered Design of a Digitally Enabled Care Pathway in a Large Health System: Qualitative Interview Study

    by Maggie McCue, Rasha Khatib, Christopher Kabir, Chris Blair, Ben Fehnert, James King, Alexander Spalding, Lara Zaki, Lambros Chrones, Anit Roy, et al.

    Background: Major depressive disorder (MDD) is a leading cause of disability worldwide. Management of chronic conditions such as MDD can be improved by enhanced patient engagement, measurement-based care (MBC), and shared decision-making (SDM). A user-centered design approach can improve the understanding of the patient journey and care team workflows and thus aid the development of digital health care innovations optimized for the needs of patients living with MDD and their primary care teams. Objective: This study aims to use qualitative research methods for the user-centered design of a digitally enabled MDD care platform, Pathway Platform, intended to enhance patient engagement, MBC, and SDM. Methods: Insights were gathered through 2 stages of qualitative interviews by a study team with expertise in qualitative research and user-centered design methods. Thematic analysis was used to generate an overarching understanding of a set of shared experiences, thoughts, or behaviors across a broad qualitative data set, including transcripts of interviews, to allow both inductive and deductive insights to emerge. Thematic analysis of interviews was supported by Dedoose (SocioCultural Research Consultants, LLC), a qualitative data analysis software tool that enables systematized coding. Findings and insights were presented based on code frequency, salience, and relevance to the research project. Results: In stage 1, interviews were conducted with 20 patients living with MDD and 15 health care providers from September 2018 to January 2019 to understand the experiences with and perceptions about the initial functionality of the Pathway app while also exploring the perceptions about potential additional features and functionality. Feedback about care team workflows and treatment approaches was collected in stage-2 interviews with 36 health care providers at 8 primary care sites. Inductive and deductive thematic analyses revealed several themes related to app functionality, patient-provider engagement, workflow integration, and patient education. Both patients and their care teams perceived the remote tracking of patient-reported outcomes via digital tools to be clinically useful and reliable and to promote MBC and SDM. However, there was emphasis on the need to enhance the flow of real-time data shared with the care team, improve trend visualizations, and integrate the data within the existing clinical workflow and educational programs for patients and their care teams. User feedback was incorporated into the iterative development of the Pathway app. Conclusions: Ongoing communication with patients living with MDD and their care teams provided an opportunity for user-centric developmental iterations of the Pathway Platform. Key insights led to further development of the patient-facing and care team–facing visit preparation features, collaborative goal-setting and goal-tracking features, patient-reported outcome summaries, and trend visualizations. The result is an enhanced digital platform with the potential to improve treatment outcomes and provide patients living with MDD additional support throughout their treatment journey.


  • Open Access

    Design and Implementation of a Digitally Enabled Care Pathway to Improve Management of Depression in a Large Health Care System: Protocol for the Implementation of a Patient Care Platform

    by Rasha Khatib, Maggie McCue, Chris Blair, Anit Roy, John Franco, Ben Fehnert, James King, Sara Sarkey, Lambros Chrones, Michael Martin, et al.

    Background: Major depressive disorder (MDD) is a serious public health concern worldwide. A treatment approach that incorporates measurement-based care (MBC) and shared decision-making between patients with MDD and their providers may foster patient engagement and improve clinical outcomes. While digital tools such as mobile apps show promise for expanding health interventions, these apps are rarely integrated into clinical practice. Objective: The primary objective of this ongoing study is to determine whether implementation of a digital tool—the Pathway Platform—in primary care improves adherence to MBC practices; here, we present the study methods. Methods: This large-scale, real-world implementation study is based on a pilot study of an earlier iteration of a mobile app (the Pathway app) that confirmed the feasibility of using the app in patients with MDD and showed a positive trend in patient engagement in the app arm. In addition, a user-centered design approach that included qualitative assessments from patients and providers was used to improve understanding of the patient journey and care team workflows. User feedback highlighted the need for enhanced features, education modules, and real-time data sharing via integration with the electronic health record. The current iteration of the Platform includes the newest version of the Pathway app, education modules for both patients and providers, and real-time patient-level data sharing with the electronic health record. The study takes place in primary care sites within the Advocate Aurora Health system in Illinois and includes adult patients with MDD who were recently prescribed monotherapy antidepressant medication (defined as a new start, medication switch, or dose change in the past 3 months). Clinical performance and selected patient outcomes will be compared before and after the implementation of the Platform. Results: Patient recruitment was completed in July 2022, with initial results expected in mid-2023. Conclusions: This study will provide useful insights into real-world integration of a digital platform within a large health system. The methods presented here highlight the unique user-centric development of the Pathway Platform, which has resulted in an enhanced digital tool with the potential to foster MBC and shared decision-making, improve patient-provider communication, and ultimately lead to optimized treatment outcomes for patients with MDD. Trial Registration: ClinicalTrials.gov NCT04891224; https://clinicaltrials.gov/ct2/show/NCT04891224 International Registered Report Identifier (IRRID): DERR1-10.2196/43788


  • Open Access

    Characterizing Longitudinal Patterns in Cognition, Mood, And Activity in Depression With 6-Week High-Frequency Wearable Assessment: Observational Study (Preprint)

    by Francesca Cormack, Maggie McCue, Caroline Skirrow, Nathan Cashdollar, Nick Taptiklis, Tempest van Schaik, Ben Fehnert, James King, Lambros Chrones, Sara Sarkey, et al.

    BACKGROUND Cognitive symptoms are an underrecognized aspect of depression that are often untreated. High-frequency cognitive assessment holds promise for improving disease and treatment monitoring. Although we have previously found it feasible to remotely assess cognition and mood in this capacity, further work is needed to ascertain the optimal methodology to implement and synthesize these techniques. OBJECTIVE The objective of this study was to examine (1) longitudinal changes in mood, cognition, activity levels, and heart rate over 6 weeks; (2) diurnal and weekday-related changes; and (3) co-occurrence of fluctuations between mood, cognitive function, and activity. METHODS A total of 30 adults with current mild-moderate depression stabilized on antidepressant monotherapy responded to testing delivered through an Apple Watch (Apple Inc) for 6 weeks. Outcome measures included cognitive function, assessed with 3 brief n-back tasks daily; self-reported depressed mood, assessed once daily; daily total step count; and average heart rate. Change over a 6-week duration, diurnal and day-of-week variations, and covariation between outcome measures were examined using nonlinear and multilevel models. RESULTS Participants showed initial improvement in the Cognition Kit N-Back performance, followed by a learning plateau. Performance reached 90% of individual learning levels on average 10 days after study onset. N-back performance was typically better earlier and later in the day, and step counts were lower at the beginning and end of each week. Higher step counts overall were associated with faster n-back learning, and an increased daily step count was associated with better mood on the same (P<.001) and following day (P=.02). Daily n-back performance covaried with self-reported mood after participants reached their learning plateau (P=.01). CONCLUSIONS The current results support the feasibility and sensitivity of high-frequency cognitive assessments for disease and treatment monitoring in patients with depression. Methods to model the individual plateau in task learning can be used as a sensitive approach to better characterize changes in behavior and improve the clinical relevance of cognitive data. Wearable technology allows assessment of activity levels, which may influence both cognition and mood.

  • Open Access

    Mobile App to Enhance Patient Activation and Patient-Provider Communication in Major Depressive Disorder Management: Collaborative, Randomized Controlled Pilot Study

    by Maggie McCue, Christopher Blair, Ben Fehnert, James King, Francesca Cormack, Sara Sarkey, Anna Eramo, Christopher Kabir, Rasha Khatib, David Kemp

    Background: Enhanced patient-provider engagement can improve patient health outcomes in chronic conditions, including major depressive disorder (MDD). Objective: We evaluated the impact of a digitally enabled care mobile app, Pathway, designed to improve MDD patient-provider engagement. Patients used a mobile interface to assess treatment progress and share this information with primary care providers (PCPs). Methods: In this 52-week, real-world effectiveness and feasibility study conducted in primary care clinics, 40 patients with MDD who were recently prescribed antidepressant monotherapy were randomized to use a mobile app with usual care (20/40, 50%) or usual care alone (20/40, 50%). Patients in the app arm engaged with the app daily for 18 weeks; a report was generated at 6-week intervals and shared with the PCPs to facilitate shared treatment decision-making discussions. The patients discontinued the app at week 18 and were followed through year 1. Coprimary outcome measures, assessed via research visits, included change from baseline in the 13-item Patient Activation Measure (PAM-13) and 7-item Patient-Provider Engagement Scale scores at week 18. Additional outcome measures included depression severity (9-item Patient Health Questionnaire [PHQ-9]) and cognitive symptoms (5-item Perceived Deficits Questionnaire–Depression). Results: All 37 patients (app arm: n=18, 49%; usual care arm: n=19, 51%) who completed the 18-week follow-up period (n=31, 84% female, mean age 36, SD 11.3 years) had moderate to moderately severe depression. Improvements in PAM-13 and PHQ-9 scores were observed in both arms. Increases in PAM-13 scores from baseline to 18 weeks were numerically greater in the app arm than in the usual care arm (mean 10.5, SD 13.2 vs mean 8.8, SD 9.4; P=.65). At 52 weeks, differences in PAM-13 scores from baseline demonstrated significantly greater improvements in the app arm than in the usual care arm (mean 20.2, SD 17.7 vs mean 1.6, SD 14.2; P=.04). Compared with baseline, PHQ-9 scores decreased in both the app arm and the usual care arm at 18 weeks (mean 7.8, SD 7.2 vs mean 7.0, SD 6.5; P=.73) and 52 weeks (mean 9.5, SD 4.0 vs mean 4.7, SD 6.0; P=.07). Improvements in 7-item Patient-Provider Engagement Scale and WHO-5 scores were observed in both arms at 18 weeks and were sustained through 52 weeks in the app arm. Improvements in WHO-5 scores at 52 weeks were significantly greater in the app arm than in the usual care arm (41.5 vs 20.0; P=.02). Conclusions: Patients with MDD will engage with a mobile app designed to track treatment and disease progression. PCPs will use the data generated as part of their assessment to inform clinical care. The study results suggest that an app-enabled clinical care pathway may enhance patient activation and benefit MDD management. Trial Registration: ClinicalTrials.gov NCT03242213; https://clinicaltrials.gov/ct2/show/NCT03242213


  • Open Access

    An App-Based Digit Symbol Substitution Test for Assessment of Cognitive Deficits in Adults With Major Depressive Disorder: Evaluation Study

    by Roger S McIntyre, Orly Lipsitz, Nelson B Rodrigues, Mehala Subramaniapillai, Flora Nasri, Yena Lee, Ben Fehnert, James King, Lambros Chrones, Kevin Kratiuk, et al.

    Background: Cognitive dysfunction is an impairing core symptom of depression. Among adults with major depressive disorder (MDD) treated with antidepressants, residual cognitive symptoms interfere with patient-reported outcomes. The foregoing characterization of cognitive symptoms provides the rationale for screening and assessing the severity of cognitive symptoms at point of care. However, clinical neurocognitive assessments are time-consuming and difficult, and they require specialist expertise to interpret them. A smartphone-delivered neurocognitive test may offer an effective and accessible tool that can be readily implemented into a measurement-based care framework. Objective: We aimed to evaluate the use of a smartphone-delivered app-based version of the established Cognition Kit Digit Symbol Substitution Test (DSST) neurocognitive assessment compared to a traditional paper-and-pencil version. Methods: Convergent validity and test-retest reliability of the 2 versions were evaluated. Patient satisfaction with the app was also assessed. Results: Assessments made using the app-based Cognition Kit DSST were highly correlated with the standard paper-and-pencil version of the test, both at the baseline visit (r=0.69, df=27; P<.001) and at the end-of-study visit (r=0.82, df=27; P<.001), and they were positively evaluated by 30 patients as being user-friendly, easy to navigate, and preferable over the paper-and-pencil version of the DSST. However, although the app-based Cognition Kit DSST was validated in patients with MDD, it still needs to be evaluated in healthy controls. Conclusions: App-based DSST may facilitate a more personalized, convenient, and cost-effective method of cognitive assessment, helping to guide measurement-based care and psychotherapeutic and pharmacologic treatment options for patients with MDD. Trial Registration: ClinicalTrials.gov NCT03999567; https://tinyurl.com/2p8pnyv7